Abstract 1059P
Background
The impact of the duration of tumor persistence within the host – tumor longevity (TL) – on patient (pt) outcomes under immune checkpoint inhibitors (ICIs) is unexplored. We hypothesized that this time parameter may influence ICIs efficacy. We investigated this association in head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC), and renal/urothelial cancer (R/UC) pts.
Methods
Retrospective, observational study including adult pts with primary/recurrent HNSCC, NSCLC, R/UC receiving ICIs (≥first line) in 2 Italian centers. Endpoints were the association between TL and: 1) progressive disease (PD) vs. complete response (CR)/ partial response (PR)/ stable disease (SD); 2) Common Terminology Criteria for Adverse Events (CTCAE) G≥3 toxicity; 3) overall survival (OS). Univariable/multivariable logistic regression model (for PD, toxicity) and Cox proportional hazards model (for OS) were used. TL, defined as time from cancer histological diagnosis to ICIs start, was included as continuous variable using 3 knots restricted cubic spline, comparing third (Q3) vs. first (Q1) quartiles.
Results
304 pts, diagnosed in 2002-2022, started ICIs in 2014-2022. TL had a right-skewed distribution [median: 15.3 (Q1-Q3, 5.5; 33.1) months]. CR, PR, SD, PD occurred in 16 (5.3%), 90 (29.6%), 65 (21.4%), 133 (43.7%) pts, respectively; G≥3 toxicity was reported in 16 (5.3%) pts and 231 (76.0%) pts died. Multivariable models adjusted for relevant variables (Table) suggested that longer TL was associated with lower PD odds (Odds Ratio [OR] Q3 vs. Q1 = 0.31; 95% CI 0.12; 0.81, p = 0.004), higher G≥3 toxicity odds (OR = 1.27; 95% CI 0.39; 4.12), lower death risk (Hazard Ratio = 0.79; 95% CI 0.49; 1.28). Table: 1059P
| Descriptive statistics (N=304) | ||
| Sex | Male | 243 (79.9%) |
| Age at diagnosis (years) | Mean (SD) | 64.7 (10.4) |
| Smoking history | Yes | 226 (74.3%) |
| No | 57 (18.8%) | |
| Unknown | 21 (6.9%) | |
| Primary site | NSCLC | 138 (45.4%) |
| HNSCC | 112 (36.5%) | |
| R/UC | 54 (17.8%) | |
| Stage at diagnosis | IV | 199 (65.5%) |
ConclusionsOur real-world, hypothesis-raising results indicate that longer TL may lead to improved response to ICIs, higher risk of G≥3 toxicity and longer OS. Clinical trial identificationEditorial acknowledgementLegal entity responsible for the studyThe authors. FundingAuthors at Niguarda Cancer Center are supported by Fondazione Oncologia Niguarda ETS. DisclosureA. Sartore Bianchi: Financial Interests, Personal, Advisory Board: Amgen, Servier, Novartis; Financial Interests, Personal, Invited Speaker: Bayer, Guardant Health, Pierre Fabre. S. Siena: Financial Interests, Advisory Board: Agenus, Amgen, AstraZeneca, Bayer, BMS, CheckmAb, Clovis, Daiichi Sankyo, Merck, Novartis, Roche-Genentech, Seattle Genetics. L.F.L. Licitra: Financial Interests, Personal, Advisory Board, for expert opinion in advisory boards: AstraZeneca, Bayer, BMS, Eisai, MSD, Boehringer Ingelheim, F. Hoffmann-La Roche Ltd, Novartis, Roche, Debiopharm International SA, Sobi, Incyte Biosciences Italy srl, Doxa Pharma srl, Amgen, Nanobiotics, GSK; Financial Interests, Institutional, Research Grant, Funds received by my institution for clinical studies and research activities in which I am involved: AstraZeneca, BMS, Boehringer Ingelheim, Celgene International, Eisai, Exelixis, Debiopharm International SA, F. Hoffmann-La Roche ltd, IRX Therapeutics, Medpace, Merck-Serono, Merck Healthcare KGaA, MSD, Novartis, Pfizer, Roche, Adlai Nortye. All other authors have declared no conflicts of interest. Resources from the same session937P - Pain, fatigue and depression symptom cluster in head and neck cancer survivorsPresenter: Iakov Bolnykh Session: Poster session 03 938TiP - Phase II TROPHY-IO-HN study of pembrolizumab ±sacituzumab govitecan in first-line recurrent /metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patientsPresenter: Amanda Psyrri Session: Poster session 03 941TiP - A phase I/IIa, open-label, dose-finding trial to evaluate safety, immunogenicity, and anti-tumour activity of VB10.16 in combination with pembrolizumab in patients with unresectable recurrent or metastatic HPV16-positive head and neck squamous cell carcinoma (R/M HNSCC)Presenter: Saira Khalique Session: Poster session 03 942TiP - A randomized controlled clinical trial of neoadjuvant immunochemotherapy vs up-front surgery in patients with locally advanced resectable oral squamous cell carcinoma (Tophill trial)Presenter: Laiping Zhong Session: Poster session 03 Resources: Abstract 945TiP - JADE: A phase (ph) III study to evaluate dostarlimab vs placebo (PBO) as sequential therapy after chemoradiation (CRT) in patients (pts) with locally advanced unresected head and neck squamous cell carcinoma (LA-HNSCC)Presenter: Jean-Pascal Machiels Session: Poster session 03 1002P - A phase Ia study of the myeloid-derived suppressor cell modulator HF1K16 in refractory and metastatic cancer patients: Preliminary efficacy and safetyPresenter: Ruofan Huang Session: Poster session 03 This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. For more detailed information on the cookies we use, please check our Privacy Policy.
|